Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

CRISPR Therapeutics is a mid-stage biotech specializing ... the Board of CR The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine ...

CRISPR Therapeutics already has financial backing from Celgene and in October announced a discovery alliance with Vertex in cystic fibrosis. Novartis has a stake in rivals Intellia Therapeutics ...